The implementation and impact of non-invasive prenatal testing (NIPT) for Down's syndrome into antenatal screening programmes: A systematic review and meta-analysis

被引:13
作者
Sebire, Elinor [1 ]
Rodrigo, Chithramali Hasanthika [1 ]
Bhattacharya, Sohinee [1 ]
Black, Mairead [1 ]
Wood, Rachael [2 ]
Vieira, Rute [1 ]
机构
[1] Univ Aberdeen, Inst Appl Hlth Sci, Sch Med Med Sci & Nutr, Aberdeen, Scotland
[2] Publ Hlth Scotland, Dept Covid 19 Hlth Protect Response, Edinburgh, Scotland
关键词
CELL-FREE DNA; FETAL DNA; MATERNAL BLOOD;
D O I
10.1371/journal.pone.0298643
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Non-invasive prenatal testing (NIPT) is a widely adopted maternal blood test that analyses foetal originating DNA to screen for foetal chromosomal conditions, including Down's syndrome (DS). The introduction of this test, which may have implications for important decisions made during pregnancy, requires continual monitoring and evaluation. This systematic review aims to assess the extent of NIPT introduction into national screening programmes for DS worldwide, its uptake, and impact on pregnancy outcomes.Methods and findings The study protocol was published in PROSPERO (CRD42022306167). We systematically searched MEDLINE, CINAHL, Scopus, and Embase for population-based studies, government guidelines, and Public Health documents from 2010 onwards. Results summarised the national policies for NIPT implementation into screening programmes geographically, along with population uptake. Meta-analyses estimated the pooled proportions of women choosing invasive prenatal diagnosis (IPD) following a high chance biochemical screening result, before and after NIPT was introduced. Additionally, we meta-analysed outcomes (termination of pregnancy and live births) amongst high chance pregnancies identified by NIPT. Results demonstrated NIPT implementation in at least 27 countries. Uptake of second line NIPT varied, from 20.4% to 93.2% (n = 6). Following NIPT implementation, the proportion of women choosing IPD after high chance biochemical screening decreased from 75% (95% CI 53%, 88%, n = 5) to 43% (95%CI 31%, 56%, n = 5), an absolute risk reduction of 38%. A pooled estimate of 69% (95% CI 52%, 82%, n = 7) of high chance pregnancies after NIPT resulted in termination, whilst 8% (95% CI 3%, 21%, n = 7) had live births of babies with DS.Conclusions NIPT has rapidly gained global acceptance, but population uptake is influenced by healthcare structures, historical screening practices, and cultural factors. Our findings indicate a reduction in IPD tests following NIPT implementation, but limited pre-NIPT data hinder comprehensive impact assessment. Transparent, comparable data reporting is vital for monitoring NIPT's potential consequences.
引用
收藏
页数:23
相关论文
共 49 条
[1]  
ACOG, ACOG guidance: NIPT summary of recommendations
[2]   First trimester serum tests for Down's syndrome screening [J].
Alldred, S. Kate ;
Takwoingi, Yemisi ;
Guo, Boliang ;
Pennant, Mary ;
Deeks, Jonathan J. ;
Neilson, James P. ;
Alfirevic, Zarko .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (11)
[3]   Non-invasive prenatal testing: a review of international implementation and challenges [J].
Allyse, Megan ;
Minear, Mollie A. ;
Berson, Elisa ;
Sridhar, Shilpa ;
Rote, Margaret ;
Hung, Anthony ;
Chandrasekharan, Subhashini .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 :113-126
[4]   Noninvasive Prenatal Testing for Fetal Aneuploidy [J].
不详 .
OBSTETRICS AND GYNECOLOGY, 2012, 120 (06) :1532-1534
[5]  
Bjerregaard L, 2017, DAN MED J, V64
[6]   Implementation of non-invasive prenatal testing within a national UK antenatal screening programme: Impact on women's choices [J].
Bowden, Bethan ;
Souza, Sikha ;
Puchades, Alice ;
Williams, Kindry ;
Morgan, Sian ;
Anderson, Sarah ;
Tucker, David ;
Hillier, Sharon .
PRENATAL DIAGNOSIS, 2022, 42 (05) :549-556
[7]  
California Department of Public Health, 2022, California
[8]   Clinical Practice Guidelines for Prenatal Aneuploidy Screening and Diagnostic Testing from Korean Society of Maternal-Fetal Medicine: (1) Prenatal Aneuploidy Screening [J].
Choe, Seung-Ah ;
Seol, Hyun-Joo ;
Kwon, Ji Young ;
Park, Chan-Wook ;
Kim, Minhyoung ;
Lee, Ji Yeon ;
Kim, Min-A ;
Hwang, Han-Sung ;
Na, Sunghun ;
Shim, Jae-Yoon ;
Kim, Kunwoo ;
Ryu, Hyun Mee .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (04)
[9]   Droplet Digital PCR for Non-Invasive Prenatal Detection of Fetal Single-Gene Point Mutations in Maternal Plasma [J].
D'Aversa, Elisabetta ;
Breveglieri, Giulia ;
Boutou, Effrossyni ;
Balassopoulou, Angeliki ;
Voskaridou, Ersi ;
Pellegatti, Patrizia ;
Guerra, Giovanni ;
Scapoli, Chiara ;
Gambari, Roberto ;
Borgatti, Monica .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (05)
[10]   Is cell-free fetal DNA testing a safe option for women in a high-risk population after combined first-trimester testing? [J].
Dap, Matthieu ;
Caffin, Lucie ;
Perdriolle-Galet, Estelle ;
Bonnet, Celine ;
Morel, Olivier .
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2022, 51 (04)